Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
Sierra's long-shot blood cancer drug scores a big win in a pivotal-stage trial.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.